Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,731,856
  • Shares Outstanding, K 1,632,199
  • Annual Sales, $ 22,561 M
  • Annual Income, $ 4,952 M
  • 36-Month Beta 0.83
  • Price/Sales 3.72
  • Price/Cash Flow 14.60
  • Price/Book 6.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.94
  • Growth Rate Est. (year over year) +106,176.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.88 +4.70%
on 01/29/19
52.80 -5.06%
on 02/21/19
+0.01 (+0.02%)
since 01/18/19
3-Month
44.30 +13.16%
on 01/03/19
54.25 -7.59%
on 12/12/18
-3.07 (-5.77%)
since 11/21/18
52-Week
44.30 +13.16%
on 01/03/19
68.88 -27.22%
on 02/27/18
-16.40 (-24.65%)
since 02/21/18

Most Recent Stories

More News
Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y

Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.

BHC : 23.51 (-2.25%)
GSK : 40.54 (-1.98%)
ETON : 7.29 (-0.27%)
BMY : 50.13 (-2.28%)
Watch for Bristol-Myer Sqb to Potentially Rebound After Falling 1.25% Yesterday

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $50.66 to a high of $51.21. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $50.75...

BMY : 50.13 (-2.28%)
Global Human Immunodeficiency Virus (HIV) Drugs Market 2019-2025 with AbbVie, Merck, Gilead Sciences, Bristol-Myers Squibb, Janssen & GSK Dominating

The "Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 - 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts" report has been added to ResearchAndMarkets.com's offering.

MRK : 79.83 (+0.50%)
GILD : 65.55 (-2.13%)
BMY : 50.13 (-2.28%)
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct

Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.

BAYRY : 19.1650 (-1.21%)
NVO : 49.66 (-0.08%)
GSK : 40.54 (-1.98%)
BMY : 50.13 (-2.28%)
Bristol-Myers Squibb Provides Update on Pending Transaction with Celgene

--Remains on Track to Hold Special Meetings of Stockholders on April 12, 2019

CELG : 88.65 (-1.94%)
CELGZ : 0.85 (+11.84%)
BMY : 50.13 (-2.28%)
How to Replicate Hedge Fund Strategies with ETFs

Liquid alternative ETFs provide access to hedge fund strategies that are not correlated with major asset classes.

MNA : 32.27 (+0.03%)
CELG : 88.65 (-1.94%)
IBM : 137.84 (-0.12%)
QAI : 29.85 (-0.07%)
BMY : 50.13 (-2.28%)
RHT : 182.90 (+0.32%)
Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo

Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.

BAYRY : 19.1650 (-1.21%)
LLY : 122.72 (+0.05%)
GSK : 40.54 (-1.98%)
BMY : 50.13 (-2.28%)
Prothena's (PRTA) Q4 Earnings Beat, Revenues Miss Estimates

Prothena's (PRTA) Q4 loss was narrower than expected, while revenues missed expectations.

CELG : 88.65 (-1.94%)
PRTA : 13.34 (-0.60%)
RHHBY : 34.5550 (-0.19%)
BMY : 50.13 (-2.28%)
Strength Seen in AstraZeneca (AZN): Stock Soars 9.3%

AstraZeneca (AZN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

AZN : 40.43 (-0.25%)
BMY : 50.13 (-2.28%)
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer

Bristol-Myers Squibb Company (NYSE: BMY) today announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant...

BMY : 50.13 (-2.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 53.72
1st Resistance Point 51.92
Last Price 50.13
1st Support Level 49.21
2nd Support Level 48.30

See More

52-Week High 68.88
Fibonacci 61.8% 59.49
Fibonacci 50% 56.59
Fibonacci 38.2% 53.69
Last Price 50.13
52-Week Low 44.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar